drugset / Trial / NCT00561821

Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)

NCT00561821

Phase 3 Completed 538 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

This study was conducted to investigate the efficacy of treatment with Org 50081 (Esmirtazapine) compared to placebo in elderly participants with chronic primary insomnia. Primary efficacy variable is Wake time After Sleep Onset (WASO), averaged over all in-treatment time points and measured by polysomnography (PSG).

Timeline

Start
2007-11-20
Primary completion
2009-12-21
Completion
2009-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Esmirtazapine Small molecule 0.5 mg
Subject Esmirtazapine Small molecule 1.5 mg
Subject Esmirtazapine Small molecule 3 mg